Neuronetics recalls 179 NeuroStar units, and Neuronetics stock costs EUR 1.71

Published on 10/20/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA posted a 179-unit recall on October 9, 2026. Neuronetics stock costs EUR 1.71 on October 20, 2026, with Q2 revenue at USD 41.57 million.

Recall and earnings context

The FDA posted a classified recall covering 179 NeuroStar units on October 9, 2026.
June 2026 quarterly revenue reached USD 41.57 million, 3.20 percent above consensus.
Neuronetics stock traded at EUR 1.71 at 1:31 p.m. CEST at Lang & Schwarz on October 20, 2026.
MarketBeat reported five brokerages with a USD 4.67 average target on October 6, 2026.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics (ISIN US64131A1051) stock costs EUR 1.71 at Lang & Schwarz on October 20, 2026, at 1:31 p.m. CEST during trading. The U.S. Food and Drug Administration posted a classified recall for the company’s NeuroStar Advanced Therapy System on October 9, 2026, covering 179 units and citing cables that did not meet production specifications.

Recall covers 179 units

The FDA record says the company began notifying customers on August 24, 2026. The affected equipment includes NeuroStar systems and upgrade kits using the HP Coil Assembly, while replacement and installation are planned at no cost to affected customers, according to the U.S. Food and Drug Administration.

What do the earnings mean?

Neuronetics reported USD 41.57 million in revenue for the quarter ended June 2026, 3.20 percent above consensus, while adjusted loss per share was USD 0.05 versus the USD 0.11 expected loss. Zacks reported the figures on August 11, 2026. The revenue comparison gives investors a measurable counterweight to the product issue, but the company remained loss-making in the quarter.

Three dated company developments

On August 11, 2026, Neuronetics reported USD 41.57 million in second-quarter revenue. On August 24, 2026, the company began customer notification for the recall involving 179 units. On October 9, 2026, the FDA classified and posted the recall, according to the U.S. Food and Drug Administration.

Analyst expectations remain materially above the euro quote. MarketBeat reported on October 6, 2026, that five brokerages held four buy ratings and one sell rating, with an average 12-month target of USD 4.67. The target is in a different currency from the Lang & Schwarz quote and is not a euro price comparison.

Euro quote and US listing

The stock was last at USD 1.91 on Nasdaq on October 19, 2026, at 4:00 p.m. ET. The Nasdaq listing and the recall are the two market facts investors can weigh against the latest quarterly revenue and loss figures.

Neuronetics was trading at EUR 1.71 at Lang & Schwarz on October 20, 2026, at 1:31 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.